Table 1.
Clinicopathological characteristics of the participants stratified by repeat biopsy results in the training cohort
| Variables | Total (n = 98) | Repeat Biopsy Results | P Value | |||
|---|---|---|---|---|---|---|
| Benign (n = 73) | Any prostate cancer (n = 25) | HGPCa (n = 11) | Any cancer vs Benign | HGPCa vs Benign | ||
| Age,yr, (mean ± SD) | 65.42 ± 7.19 | 65.16 ± 7.61 | 66.16 ± 5.84 | 64.55 ± 4.34 | .55 | .79 |
| f/t PSA ratio, %, (mean ± SD) | 16.55 ± 4.94 | 17.15 ± 4.75 | 14.80 ± 5.16 | 13.82 ± 5.72 | .039 | .038 |
| Clinical serum PSA, ng/mL, (mean ± SD) | 8.30 ± 4.52 | 7.74 ± 3.79 | 9.92 ± 5.99 | 10.88 ± 6.39 | .037 | .023 |
| No. of suspicious DRE, n, (%) | 7 (7.14) | 5 (6.85) | 2 (8.00) | 1 (9.09) | 1.00 | .58 |
| ASAP history, n, (%) | 13 (13.27) | 6 (8.22) | 7 (28.00) | 2 (18.18) | .19 | .28 |
| HGPIN history, n, (%) | 13 (13.27) | 9 (12.33) | 4 (16.00) | 1 (9.09) | .73 | 1.00 |
| No. of previous biopsy cores (mean ± SD) | 7.01 ± 1.85 | 6.9 ± 1.88 | 7.1 ± 1.79 | 7.55 ± 1.37 | .73 | .31 |
HGPCa, High grade prostate cancer